News

Preliminary, interim, three-year MINIjectTM data show strong performance and no ECD safety concerns

Promising preliminary, interim three-year data on iSTAR Medical’s Minimally Invasive Glaucoma Surgery (MIGS) device, MINIjectTM, showed strong performance and no endothelial cell density (ECD) safety concerns in glaucoma patients, confirming the positive trend observed so far as part of the STAR-I trial. The data have been presented at the Deutsche Ophthalmologische Gesellschaft (DOG) congress, the […]

MINIjectTM data featuring at German DOG virtual meeting

Results from MINIject’s European STAR-II trial and from the long-term follow-up trial STAR-GLOBAL will feature at the Deutsche Ophthalmologische Gesellschaft (DOG) congress, the annual meeting of the German Ophthalmology Society taking place 30 September to 3 October. The 18-month data from the European STAR-II trial will be presented on-demand by the global leading ophthalmologist, Professor […]

iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients

World-leading surgeons to join iSTAR Medical’s STAR-V study WAVRE, Belgium — 15 July 2021: iSTAR Medical, a med-tech company developing minimally-invasive implants for glaucoma surgery (MIGS), announced today that the U.S. Food and Drug Administration (FDA) granted it Investigational Device Exemption (IDE) to start a pivotal trial with MINIjectTM. The STAR-V study will investigate MINIjectTM […]

iSTAR Medical recruits Paul van Hagen as CFO

WAVRE, Belgium — 29 June 2021: iSTAR Medical, a med-tech company developing minimally-invasive implants for glaucoma treatment, announced today that Paul van Hagen has joined the company as Chief Financial Officer (CFO).

MINIject interim three-year data to be presented at WGC-2021

Interim three-year data on iSTAR Medical’s Minimally Invasive Glaucoma Surgery (MIGS) device MINIjectTM will be presented at the World Glaucoma Congress WGC-21, virtually hosted by the Japan Glaucoma Society between 30th June and 3rd July.